TY - JOUR
T1 - MTNR1B G24E variant associates With BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans
AU - Andersson, Ehm A
AU - Holst, Birgitte
AU - Sparsø, Thomas
AU - Grarup, Niels
AU - Banasik, Karina
AU - Holmkvist, Johan
AU - Jørgensen, Torben
AU - Borch-Johnsen, Knut
AU - Egerod, Kristoffer L
AU - Lauritzen, Torsten
AU - Sørensen, Thorkild I A
AU - Bonnefond, Amélie
AU - Meyre, David
AU - Froguel, Philippe
AU - Schwartz, Thue W
AU - Pedersen, Oluf
AU - Hansen, Torben
PY - 2010/6
Y1 - 2010/6
N2 - OBJECTIVE - Common variants in the melatonin receptor type 1B (MTNR1B) locus have been shown to increase fasting plasma glucose (FPG) and the risk of type 2 diabetes. The aims of this study were to evaluate whether nonsynonymous variants in MTNR1B associate with monogenic forms of hyperglycemia, type 2 diabetes, or related metabolic traits. RESEARCH DESIGN AND METHODS - MTNR1B was sequenced in 47 probands with clinical maturity-onset diabetes of the young (MODY), in 51 probands with early-onset familial type 2 diabetes, and in 94 control individuals. Six nonsynonymous variants (G24E, L60R, V124I, R138C, R231H, and K243R) were genotyped in up to 22,142 Europeans. Constitutive and melatonin-induced signaling was characterized for the wild-type melatonin receptor type 1B (MT2) and the 24E, 60R, and 124I MT2 mutants in transfected COS-7 cells. RESULTS - No mutations in MTNR1B were MODY specific, and none of the investigated MTNR1B variants associated with type 2 diabetes. The common 24E variant associated with increased prevalence of obesity (odds ratio 1.20 [1.08 -1.34]; P = 8.3 × 10-4) and increased BMI (β = 0.5 kg/m2; P = 1.2 × 10-5) and waist circumference (β = 1.2 cm; P = 9 × 10-6) in combined Danish and French study samples. 24E also associated with decreased FPG (β = -0.08 mmol/l; P = 9.2 × 10-4) in the Danish Inter99 population. Slightly decreased constitutive activity was observed for the MT2 24E mutant, while the 124I and 60R mutants displayed considerably decreased or completely disrupted signaling, respectively. CONCLUSIONS - Nonsynonymous mutations in MTNR1B are not a common cause of MODY or type 2 diabetes among Danes. MTNR1B 24E associates with increased body mass and decreased FPG. Decreased MT2 signaling does apparently not directly associate with FPG or type 2 diabetes.
AB - OBJECTIVE - Common variants in the melatonin receptor type 1B (MTNR1B) locus have been shown to increase fasting plasma glucose (FPG) and the risk of type 2 diabetes. The aims of this study were to evaluate whether nonsynonymous variants in MTNR1B associate with monogenic forms of hyperglycemia, type 2 diabetes, or related metabolic traits. RESEARCH DESIGN AND METHODS - MTNR1B was sequenced in 47 probands with clinical maturity-onset diabetes of the young (MODY), in 51 probands with early-onset familial type 2 diabetes, and in 94 control individuals. Six nonsynonymous variants (G24E, L60R, V124I, R138C, R231H, and K243R) were genotyped in up to 22,142 Europeans. Constitutive and melatonin-induced signaling was characterized for the wild-type melatonin receptor type 1B (MT2) and the 24E, 60R, and 124I MT2 mutants in transfected COS-7 cells. RESULTS - No mutations in MTNR1B were MODY specific, and none of the investigated MTNR1B variants associated with type 2 diabetes. The common 24E variant associated with increased prevalence of obesity (odds ratio 1.20 [1.08 -1.34]; P = 8.3 × 10-4) and increased BMI (β = 0.5 kg/m2; P = 1.2 × 10-5) and waist circumference (β = 1.2 cm; P = 9 × 10-6) in combined Danish and French study samples. 24E also associated with decreased FPG (β = -0.08 mmol/l; P = 9.2 × 10-4) in the Danish Inter99 population. Slightly decreased constitutive activity was observed for the MT2 24E mutant, while the 124I and 60R mutants displayed considerably decreased or completely disrupted signaling, respectively. CONCLUSIONS - Nonsynonymous mutations in MTNR1B are not a common cause of MODY or type 2 diabetes among Danes. MTNR1B 24E associates with increased body mass and decreased FPG. Decreased MT2 signaling does apparently not directly associate with FPG or type 2 diabetes.
U2 - 10.2337/db09-1757
DO - 10.2337/db09-1757
M3 - Journal article
C2 - 20200315
SN - 0012-1797
VL - 59
SP - 1539
EP - 1548
JO - Diabetes
JF - Diabetes
IS - 6
ER -